- Home
- TRC vs INBX Comparison
TRC vs INBX Comparison
Compare TRC & INBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TRC
- INBX
- Stock Information
- Founded
- TRC 1843
- INBX 2010
- Country
- TRC United States
- INBX United States
- Employees
- TRC 88
- INBX N/A
- Industry
- TRC Real Estate
- INBX Biotechnology: Pharmaceutical Preparations
- Sector
- TRC Finance
- INBX Health Care
- Exchange
- TRC Nasdaq
- INBX Nasdaq
- Market Cap
- TRC 419.0M
- INBX 430.2M
- IPO Year
- TRC N/A
- INBX 2020
- Fundamental
- Price
- TRC $15.97
- INBX $82.27
- Analyst Decision
- TRC
- INBX Hold
- Analyst Count
- TRC 0
- INBX 2
- Target Price
- TRC N/A
- INBX N/A
- AVG Volume (30 Days)
- TRC 85.5K
- INBX 736.9K
- Earning Date
- TRC 11-06-2025
- INBX 11-14-2025
- Dividend Yield
- TRC N/A
- INBX N/A
- EPS Growth
- TRC N/A
- INBX N/A
- EPS
- TRC N/A
- INBX N/A
- Revenue
- TRC $45,307,000.00
- INBX $1,400,000.00
- Revenue This Year
- TRC N/A
- INBX $563.00
- Revenue Next Year
- TRC N/A
- INBX $230.77
- P/E Ratio
- TRC N/A
- INBX N/A
- Revenue Growth
- TRC 14.79
- INBX N/A
- 52 Week Low
- TRC $14.71
- INBX $10.81
- 52 Week High
- TRC $19.39
- INBX $86.64
- Technical
- Relative Strength Index (RSI)
- TRC 49.51
- INBX 85.42
- Support Level
- TRC $15.44
- INBX $28.16
- Resistance Level
- TRC $16.00
- INBX $83.95
- Average True Range (ATR)
- TRC 0.34
- INBX 6.96
- MACD
- TRC 0.04
- INBX 3.63
- Stochastic Oscillator
- TRC 56.99
- INBX 92.56
About TRC Tejon Ranch Co
Tejon Ranch Co is a diversified real estate development and agribusiness company committed to responsibly using its land and resources to meet the housing, employment, and lifestyle needs of Californians and create value for its shareholders. It has five segments namely Real Estate - Commercial/Industrial, Real Estate - Resort/Residential, Mineral Resources, Farming, and Ranch Operations.
About INBX Inhibrx Inc.
Inhibrx Biosciences Inc is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize their multivalent formats where the precise valency can be optimized in a target-centric way to mediate what experts consider to be the predominant agonist function.